請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50029
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Jen-Yu Chang | en |
dc.contributor.author | 張人予 | zh_TW |
dc.date.accessioned | 2021-06-15T12:28:08Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-08 | |
dc.identifier.citation | 1. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-88S.
2. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S. 3. Group TEAFTS. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med. 1995;333(1):5-10. 4. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11-17. 5. Ansell JE, Oertel LB, Wittkowsky AK. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. Third ed: Wolters Kluwer Health; 2009. 6. Fang MC, Machtinger EL, Wang F, Schillinger D. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med. 2006;21(8):841-846. 7. Kauffman YS, Schroeder AE, Witt DM. Patient Specific Factors Influencing Adherence to INR Monitoring. Pharmacotherapy. 2015;35(8):740-747. 8. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. American heart journal. 1996;132(5):1095-1100. 9. Dib JG, Mohammed K, Momattin HI, Alshehri AM. Implementation of pharmacist-managed anticoagulation clinic in a saudi arabian health center. Hosp Pharm. 2014;49(3):260-268. 10. Airee A, Guirguis AB, Mohammad RA. Clinical outcomes and pharmacists' acceptance of a community hospital's anticoagulation management service utilizing decentralized clinical staff pharmacists. Ann Pharmacother. 2009;43(4):621-628. 11. Bungard TJ, Gardner L, Archer SL, et al. Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med. 2009;3(1):e16-21. 12. Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH. Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. Br J Clin Pharmacol. 2006;62(5):601-609. 13. Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23(3):173-181. 14. Locke C, Ravnan SL, Patel R, Uchizono JA. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy. 2005;25(5):685-689. 15. Poon IO, Lal L, Brown EN, Braun UK. The impact of pharmacist-managed oral anticoagulation therapy in older veterans. J Clin Pharm Ther. 2007;32(1):21-29. 16. Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(11):2418-2427. 17. Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105-112. 18. Thanimalai S, Shafie AA, Hassali MA, Sinnadurai J. Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital. Int J Clin Pharm. 2013;35(5):736-743. 19. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ. 2003;169(4):293-298. 20. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127(5):1515-1522. 21. Wong YM, Quek YN, Tay JC, Chadachan V, Lee HK. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration. J Clin Pharm Ther. 2011;36(5):585-591. 22. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641-1647. 23. Garwood CL, Curtis KD, Belanger GJ, et al. Preliminary data from a pharmacist-managed anticoagulation clinic embedded in a multidisciplinary patient-centered medical home: a coordinated quality, cost-savings model. J Am Geriatr Soc. 2014;62(3):536-540. 24. Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30(4):330-338. 25. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother. 2007;41(3):496-501. 26. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021-1033. 27. Johnson SG. Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist. J Manag Care Pharm. 2009;15(6 Suppl B):S19-25. 28. Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy. 2011;31(7):686-694. 29. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004;10(2):159-165. 30. Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A, Jeanpeerapong N. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. Thromb Res. 2013;132(4):437-443. 31. You JH, Chan FW, Wong RS, Cheng G. Cost-effectiveness of two models of management for patients on chronic warfarin therapy--a Markov model analysis. Thromb Haemost. 2003;90(6):1106-1111. 32. AHFS drug information [electronic resource]. Bethesda, MD : Published by authority of the Board of Directors of the American Society of Hospital Pharmacists, c1989-. Accessed May 09, 2016. 33. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. 34. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309-315. 35. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol. 2005;59(5):582-587. 36. Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. J Cardiol. 2015;65(3):175-177. 37. Inoue H. Thromboembolism in patients with nonvalvular atrial fibrillation: comparison between Asian and Western countries. J Cardiol. 2013;61(1):1-7. 38. Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacother. 2000;34(12):1395-1401. 39. Yu HY, Liu CH, Chen YS, Wang SS, Chu SH, Lin FY. Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement. J Formos Med Assoc. 2005;104(4):236-243. 40. Cheung CM, Tsoi TH, Huang CY. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis. 2005;20(2):114-119. 41. 林欣儀, 陳以雯, 康皓程, et al. Warfarin在亞洲族群之治療目標準則. 臺灣臨床藥學雜誌. 2015;23(3):189-202. 42. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213-216. 43. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. 44. Duxbury BM. Therapeutic control of anticoagulant treatment. Br Med J (Clin Res Ed). 1982;284(6317):702-704. 45. Proietti M, Lip GY. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range. Am J Med. 2016. 46. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968-977. 47. Pokorney SD, Simon DN, Thomas L, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170(1):141-148, 148 e141. 48. Pastori D, Pignatelli P, Saliola M, et al. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Int J Cardiol. 2015;201:513-516. 49. Chan PH, Li WH, Hai JJ, et al. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Can J Cardiol. 2015. 50. An J, Niu F, Lang DT, et al. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. J Am Heart Assoc. 2015;4(7). 51. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84-91. 52. Rosendaal FR. The Scylla and Charybdis of Oral Anticoagulant Treatment. New England Journal of Medicine. 1996;335(8):587-589. 53. Choe HM, Kim J, Choi KE, Mueller BA. Implementation of the first pharmacist-managed ambulatory care anticoagulation clinic in South Korea. Am J Health Syst Pharm. 2002;59(9):872-874. 54. Liu K, Lu H, Gong J, Wong I, Chan E. Feasibility of Pharmacist-Participated Anticoagulation Management Service (PAMS) in A Regional Hospital in Shanghai: A Pilot Study. Paper presented at: Drug Safety2014. 55. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24(8):953-963. 56. Hosmane SR, Tucker J, Osman D, Williams S, Waterworth P. Inpatient Oral Anticoagulation Management by Clinical Pharmacists: Safety and Cost effectiveness. J Clin Med Res. 2010;2(2):90-92. 57. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995;15(6):732-739. 58. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm. 1985;19(7-8):575-580. 59. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. OUP Oxford; 2006. 60. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409. 61. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338. 62. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11(38):iii-iv, ix-66. 63. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28(1):61-74. . 64. Verhoef TI, Redekop WK, Langenskiold S, et al. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J. 2016. 65. Chong HY, Saokaew S, Dumrongprat K, et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res. 2014;134(6):1278-1284. 66. Chevalier J, Delaitre O, Hammes F, de Pouvourville G. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Arch Cardiovasc Dis. 2014;107(6-7):381-390. 67. Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(6):575-585. 68. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690-698. 69. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. 70. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114(6):1277-1289. 71. Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes. 2014;7(5):664-669. 72. Lind M, Fahlen M, Kosiborod M, Eliasson B, Oden A. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012;129(1):32-35. 73. Lee VW, You JH, Lee KK, Chau TS, Waye MM, Cheng G. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005;20(1):33-38. 74. 國立臺灣大學醫學院附設醫院: 抗凝血門診口服抗凝血藥品warfarin 建議使用準則(standing order). 2013. http://140.112.125.99/phar/intranet/druginfo/. Accessed Jan. 19, 2016. 75. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. doi: 110.1378/chest.1308-0670. 76. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. 77. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. 78. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Communications in Statistics - Simulation and Computation. 2009;38(6):1228-1234. 79. Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied logistic regression. Vol 398: John Wiley & Sons; 2013. 80. Pencina MJ, D’Agostino RB, Sr. Evaluating discrimination of risk prediction models: The c statistic. JAMA. 2015;314(10):1063-1064. 81. 內政部統計處. 101 年國人零歲平均餘命估測結果. 2012; http://www.moi.gov.tw/stat/life.aspx. Accessed May 29, 2014. 82. 康皓程. 建構新型態之藥事照護 : 抗凝血門診 (Establishment of a novel pharmaceutical care : an anticoagulation clinic) [Master Thesis]. Taipei: Graduate Institute of Clinical Pharmacy, National Taiwan University; 2014. 83. Chang KC, Lee HC, Huang YC, et al. Cost-effectiveness analysis of stroke management under a universal health insurance system. J Neurol Sci. 2012;323(1-2):205-215. 84. Gresham GE, Stason WB, Duncan PW. Post-stroke rehabilitation. Vol 95: DIANE Publishing; 1997. 85. Chang KC, Tseng MC. Costs of acute care of first-ever ischemic stroke in Taiwan. Stroke. 2003;34(11):e219-221. 86. 內政部統計處. 101 年臺灣地區簡易生命表. 2012; http://www.moi.gov.tw/stat/life.aspx. Accessed May 29, 2014. 87. Chien KL, Su TC, Hsu HC, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010;139(2):173-180. 88. Lee C-H, Cheng C-L, Lin L-J, Tsai L-M, Yang Y-HK. Epidemiology and Predictors of Short-Term Mortality in Symptomatic Venous Thromboembolism. Circulation Journal. 2011;75(8):1998-2004. 89. Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation. 2010;122(11):1116-1123. 90. Lo PH, Huang YF, Chang CC, et al. Risk and mortality of gastrointestinal hemorrhage in patients with thrombocytopenia: Two nationwide retrospective cohort studies. Eur J Intern Med. 2016;27:86-90. 91. Wu C-W, Kang H-C, Lin S-Y, et al. 臺灣藥師抗凝血門診服務 (A pharmacist anti-coagulation clinic in Taiwan). Formosa Journal of Clinical Pharmacy. 2016;24(2):81-85. 92. National Health Insurance Research Database T. Introduction to the National Health Insurance Database (NHIRD). 2012; http://nhird.nhri.org.tw/. Accessed Feb 17, 2016. 93. 行政院主計總處. 消費者物價商品性質分類指數. 2012; www.dgbas.gov.tw. Accessed Feb 17, 2016. 94. 衛生福利部統計處. 台灣地區年中人口數與全民健康保險平均點值表. 2014; http://www.mohw.gov.tw/. Accessed May 29, 2014. 95. Lee HC, Chang KC, Huang YC, et al. Readmission, mortality, and first-year medical costs after stroke. J Chin Med Assoc. 2013;76(12):703-714. 96. Lee HY, Hwang JS, Jeng JS, Wang JD. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke. 2010;41(4):739-744. 97. Jugrin AV, Ustyugova A, Urbich M, Lamotte M, Sunderland T. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK. Thromb Haemost. 2015;114(4):778-792. 98. 國家醫療科技評估中心 (National Institute of Health Technology Assessment T. 醫療科技評估方法學指引. 2013; http://nihta.cde.org.tw/. Accessed Mar 14, 2016. 99. Organization WH. Cost effectiveness and strategic planning (WHO-CHOICE). 2016; http://www.who.int/choice/en/. Accessed Feb 17, 2016. 100. 行政院主計總處. 101年國民所得統計常用資料. 2012; www.dgbas.gov.tw. Accessed Feb 17, 2016. 101. Masaki N, Suzuki M, Matsumura A, Maruyama Y, Hashimoto Y. Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern Med. 2010;49(16):1711-1716. 102. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother. 2002;36(2):200-204. 103. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry. Circ J. 2015;79(11):2345-2352. 104. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(2):300-306. 105. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin. 2008;26(2):157-167, v. 106. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9(3):283-292. 107. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983. 108. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008;25(1):61-66. 109. Chen PC, Lip GY, Yeh G, Lin HJ, Chien KL. Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One. 2015;10(4):e0125257. 110. Chan Y-H, Yen K-C, See L-C, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke. 2016;47(2):441-449. 111. Kayssi A, Roche-Nagle G. Postthrombotic syndrome. Canadian Medical Association Journal. 2014;186(1):62-62. 112. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I-22-I-30. 113. Rascati K. Essentials of pharmacoeconomics. 2nd ed: Lippincott Williams & Wilkins; 2013. 114. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed: Oxford university press; 2015. 115. van Eeden M, van Heugten C, van Mastrigt GA, van Mierlo M, Visser-Meily JM, Evers SM. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke. BMJ Open. 2015;5(11):e008220. 116. Jakobsen M, Kolodziejczyk C, Fredslund EK, Poulsen PB, Dybro L, Johnsen SP. Societal Costs of First-Incident Ischemic Stroke in Patients with Atrial Fibrillation-A Danish Nationwide Registry Study. Value Health. 2016;19(4):413-418. 117. Wittenberg E, Prosser LA. Disutility of illness for caregivers and families: a systematic review of the literature. Pharmacoeconomics. 2013;31(6):489-500. 118. Ganapathy V, Graham GD, DiBonaventura MD, Gillard PJ, Goren A, Zorowitz RD. Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity. Clin Interv Aging. 2015;10:1793-1802. 119. Das S, Hazra A, Ray BK, et al. Burden among stroke caregivers: results of a community-based study from Kolkata, India. Stroke. 2010;41(12):2965-2968. 120. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S. Does Pay-for-Performance Improve the Quality of Health Care? Annals of Internal Medicine. 2006;145(4):265-272. 121. Chung KC, Shauver MJ. Measuring quality in healthcare and its implications for pay-for-performance initiatives. Hand clinics. 2009;25(1):71-vii. 122. de Bruin SR, Baan CA, Struijs JN. Pay-for-performance in disease management: a systematic review of the literature. BMC Health Services Research. 2011;11(1):1-14. 123. Van Herck P, De Smedt D, Annemans L, Remmen R, Rosenthal MB, Sermeus W. Systematic review: Effects, design choices, and context of pay-for-performance in health care. BMC Health Services Research. 2010;10(1):1-13. 124. Hsieh HM, Gu SM, Shin SJ, Kao HY, Lin YC, Chiu HC. Cost-Effectiveness of a Diabetes Pay-For-Performance Program in Diabetes Patients with Multiple Chronic Conditions. PLoS One. 2015;10(7):e0133163. 125. Hsieh HM, Tsai SL, Shin SJ, Mau LW, Chiu HC. Cost-effectiveness of diabetes pay-for-performance incentive designs. Med Care. 2015;53(2):106-115. 126. Hsieh HM, Lin TH, Lee IC, Huang CJ, Shin SJ, Chiu HC. The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study. Prev Med. 2016;85:53-59. 127. Chen YC, Lee CT, Lin BJ, Chang YY, Shi HY. Impact of pay-for-performance on mortality in diabetes patients in Taiwan: A population-based study. Medicine (Baltimore). 2016;95(27):e4197. 128. Li YH, Tsai WC, Khan M, et al. The effects of pay-for-performance on tuberculosis treatment in Taiwan. Health Policy Plan. 2010;25(4):334-341. 129. Kuo RN, Chung KP, Lai MS. Effect of the Pay-for-Performance Program for Breast Cancer Care in Taiwan. J Oncol Pract. 2011;7(3 Suppl):e8s-e15s. 130. Eijkenaar F. Key issues in the design of pay for performance programs. Eur J Health Econ. 2013;14(1):117-131. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50029 | - |
dc.description.abstract | 研究背景:
口服抗凝血藥品warfarin被廣泛被使用於治療或是預防血栓事件,然而其療效區間狹窄,不合適的劑量可能使病人暴露於產生嚴重出血或是血栓事件的風險之下。因此,透過個人化的治療管理才能確保warfarin的療效以及安全性,而抗凝血藥師門診監測warfarin療效 (pharmacist-assisted warfarin monitoring, PAWM) 已在許多其他國家被證實可以提升warfarin的效果及安全性並具有成本效益。 臺大醫院於2012年開辦了全國第一個病人付費之抗凝血藥師門診,而至今其療效成果及成本效益尚未與一般醫師門診照護 (usual care, UC) 進行比較。 研究目的: 了解臺大醫院抗凝血藥師門診的病人特質,並與僅接受一般醫師門診照護的病人進行比較,評估藥師抗凝血門診的療效成果及成本效益。 研究方法: 首先,以臺大醫院資料庫進行一回溯性研究,了解臺大醫院抗凝血藥師門診的病人特質、評估藥師監測warfarin的療效成果。透過此一回溯性研究所獲得的資料與其他文獻的數據,再進一步針對藥師抗凝血門診進行成本效益評估。 1.了解抗凝血藥師門診的病人特質及評估藥師監測warfarin的療效成果 收納自民國101年2月至104年4月曾接受過warfarin治療的病人,分成曾經接受過抗凝血藥師門診照護或是未接受過抗凝血藥師門診照護兩組病人。經1:4 傾向分數配對 (propensity score matching),降低選擇性偏差,找出兩組間可以互相比較的病人。計算INR (international normalized ratio) 落於治療範圍內之時間 (time in therapeutic range, TTR)、嚴重出血事件發生率、嚴重血栓事件發生率,做為評估療效成果的依據。 2.抗凝血藥師門診監測warfarin療效的成本效益分析 本研究應用一週期長度為一個月的馬可夫模型來模擬抗凝血藥師門診監測warfarin療效相較於僅接受一般醫師照護之成本效益。本研究之馬可夫模型模擬之時間長度為20年,假設所有病人於60歲時進入研究,且在被納入研究時皆處於“無事件”的狀態,隨著時間的演變,病人可能產生嚴重血栓、嚴重出血事件、事件發生後相關的後遺症或死亡。 “無事件”狀態在本模型裡又細分成低於療效區間、 介於療效區間以及高於療效區間,以展現病人在不同的狀態下有不同的warfarin相關不良事件發生機率。抗凝血藥師門診理論上應能將病人的INR維持在療效區間的時間提高,以減少病人產生不良事件的機率。 所有套入馬可夫模型之相關數據盡量透過臺大醫院資料庫、健保資料庫得出或是引用臺灣文獻,包含事件發生機率、費用、臨床事件相關之生活品質。所有的花費計算以2012年新臺幣 (NT$) 為基準,並且引入每年3%的折現比率。 除基準值分析外,本研究亦引入單維敏感度分析(one-way sensitivity analysis)、機率性敏感度分析(probabilistic sensitivity analysis, PSA)來測試模型的不確定性是否會影響結果分析。 研究結果: 1.了解抗凝血藥師門診的病人特質及評估藥師監測warfarin的療效成果 經傾向分數配對後,共計納入1,590位病人進行結果分析,其中318個病人為接受抗凝血藥師門診照護組,1,272個病人為僅接受一般醫師照護組。以INR區間1.5-3.0而言,接受抗凝血藥師門診照護組之INR落於治療範圍內之時間明顯高於僅接受一般醫師照護組(78.4% v.s. 54.9%, p < 0.001)。即使改變INR區間至1.8-2.0 (53.3% v.s. 35.5%, p <0.001)及2.0-3.0 (33.6% v.s. 24.5%, p<0.001),結果都顯示抗凝血藥師門診照護組之INR受到控制的情形較佳。Warfarin相關之不良事件發生率則因受限於醫院資料庫的偵測限制,一般醫師門診組的不良事件發生率可能被大幅低估,導致兩組病人之結果無法相互比較。 2.抗凝血藥師門診監測warfarin療效的成本效益分析 以健保署的觀點而言,在20年的研究區間之下,抗凝血藥師門診照護組相較於僅接受一般醫師照護組之病人平均每人可以增加0.13個品質校正生活年 (quality-adjusted life-year, QALY)及NT$53,850的額外花費,而增加成本效益比 (incremental cost-effectiveness ratio, ICER) 為NT$410,749,代表每多增加一品質校正生活年需多花費NT$410,749,小於2012年臺灣之人均國民所得 (gross domestic product per capita, GDP per capita) NT$631,142。依據世界衛生組織 (World Health Organization, WHO) 的建議,若增加成本效益比小於人均國民所得,則該醫療方案相對於其對照方案為非常符合經濟效益。 敏感度分析顯示我們的分析結果穩健度高,且以人均國民所得做為閾值的話,抗凝血藥師門診照護有86%的機率會是非常符合經濟效益。 結論: 透過臺大醫院之抗凝血藥師門診監測warfarin可以將病人的INR控制的更加良好,且相較於僅接受一般醫師門診照護來說非常符合成本效益。臺灣相較於其他歐美國家,醫療支出費用相對低廉,因此透過將INR控制良好進而減少嚴重血栓或出血事件而減少相關的花費理論上應差距不大。不過本研究結果顯示,即使在這樣的情況下再加上抗凝血藥師門診所需要增加的花費,抗凝血藥師門診仍符合經濟效益。因此,健保署應考慮給付抗凝血藥師門診監測warfarin療效的服務。 | zh_TW |
dc.description.abstract | Background:
Warfarin as a widely prescribed anticoagulant, has been proved to be effective in preventing or treating thromboembolic (TE) events. Due to the narrow therapeutic range of warfarin, inappropriate dosing may lead to major bleeding or TE events. Individualized monitoring of the international normalized ratio (INR) is required to enhance the safety and efficacy of the warfarin therapy. The pharmacist-assisted warfarin monitoring (PAWM) has been demonstrated to be effective and cost-effective in reducing warfarin-associated adverse events in Western countries. The first official pharmacist-led anticoagulation clinic offering patient-paid PAWM services in Taiwan was established in 2012 at the National Taiwan University Hospital (NTUH). To date, the clinical effectiveness and cost-effectiveness of the PAWM program compared to the usual care (UC) have not yet been evaluated. Objectives: To understand the patient characteristics, and to investigate the clinical effectiveness and cost-effectiveness of the PAWM program at the NTUH. Methods: We first used the NTUH databases to understand the features of the PAWM, including patient characteristics and clinical effectiveness. Along with these epidemiological data and data from literatures, a cost-effective analysis was performed. 1.Baseline Characteristics and Clinical Effectiveness of the PAWM A retrospective study from February 1, 2012 to April 30, 2015 was conducted in patients receiving warfarin with or without PAWM at the NTUH. A 1:4 propensity score matching was introduced to reduce the selection bias in comparing the outcomes of the two study groups. Time in therapeutic range (TTR) and major TE/bleeding even rates were captured to understand the clinical effectiveness of the PAWM compared to UC. 2.Cost-Effectiveness Analysis of the PAWM A Markov model with a one-month cycle length and 20-year time horizon was employed to assess the cost-effectiveness of the PAWM compared to the UC. Patients receiving warfarin entered the hypothetical cohort at the age of 60 and were then staying event-free or developing major TE/bleeding events followed by sequelae or death. The no-event state was split into supratherapeutic, within therapeutic, and subtherapeutic, since the patients were considered at a higher risk of encountering warfarin-associated adverse events if being out of therapeutic range. The performance of the PAWM was assumed to be in lined with the ability of keeping the patients in the therapeutic range. The likelihood of events, costs, utilities were derived from the NTUH databases, the Taiwan National Health Insurance Research Database (NHIRD) and Taiwanese literatures if applicable. All the costs were adjusted to the value of the New Taiwanese dollar (NT$) in 2012 and discounted with a rate of 3%. One-way sensitivity analysis and probabilistic analysis were performed to examine the robustness of our results. Results: 1.Baseline Characteristics and Clinical Effectiveness of the PAWM After the propensity score matching, 1,590 patients were enrolled in the study, including 318 patients in the PAWM group and 1,272 patients in the UC group. The TTR was significantly higher in the PAWM group (78.4% v.s. 54.9%, p < 0.001) when the INR range was set as 1.5-3.0. The results remained favoring the PAWM even if altering the INR range to 1.8-3.0 (53.3% v.s. 35.5%, p < 0.001) and 2.0-3.0 (33.6% v.s. 24.5%, p < 0.001). Owing to the small sample size and potential detection biases under the scope of hospital databases, the incidence rates of warfarin-associated adverse events were considered greatly underestimated in the UC group. Therefore, the incidence rates were believed to be incomparable in the two study groups. 2.Cost-Effectiveness Analysis of the PAWM From the payer’s perspective (i.e. National Health Insurance Administration, NHIA), the PAWM resulted in an average of 0.13 QALYs gained and a cost increment of NT$53,850 per person compared to UC over a 20-year horizon. The incremental cost-effectiveness ratio (ICER) was NT$410,749 per QALY gained. As the ICER was less than a gross domestic product (GDP) per capita (NT$631,142), the PAWM was considered to be very cost-effective according to the World Health Organization (WHO) recommendation. The sensitivity analyses suggested that our result was robust, and the PAWM had an 86% probability of being very-cost effective. Conclusions: The PAWM at the NTUH was proved to enhance the quality of INR control. Additionally, the PAWM was demonstrated to be very cost-effective, even if the costs saved from avoiding adverse events were thought to be minimal due to the low medical expenses in Taiwan. Our findings provide the evidence on the cost-effectiveness of the PAWM, and policy makers should consider reimbursing such service. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:28:08Z (GMT). No. of bitstreams: 1 ntu-105-R02451001-1.pdf: 1726497 bytes, checksum: b99bf6b7fa0a55a08273929ab18abe33 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract v Table of Contents viii List of Figures xi List of Tables xii Abbreviations xiii Chapter 1: Introduction 1 Chapter 2: Literature Review 3 2.1 Anticoagulation Therapy 3 2.1.1 Current Status of Warfarin as an Oral Anticoagulant 3 2.1.2 Adverse Events and Therapeutic Range of Warfarin in Asian Populations 3 2.2 Warfarin Management Services 6 2.2.1 Warfarin Management Services and the Quality Improvement Measures 6 2.2.2 Clinical Effectiveness of the PAWM program 7 2.3 Cost-Effectiveness Analysis 9 2.3.1 Approaches of Evaluating the Economic Impact of the PAWM Program 9 2.3.2 Evaluating the Cost-Effectiveness of the PAWM Program Using Markov Model 9 Chapter 3: Study Objectives 11 Chapter 4: Methods 12 4.1 Study Framework 12 4.2 Aim 1 & Aim 2: The Baseline Characteristics and Clinical Effectiveness of the PAWM 13 4.2.1 Data Sources 13 4.2.2 Study Cohort 14 4.2.3 Baseline Characteristics and Comorbid Diseases 15 4.2.4 Outcome Measures 15 4.2.5 Sensitivity Analysis 16 4.2.6 Statistical Analysis 17 4.2.6.1 Descriptive Analysis 17 4.2.6.2 Propensity Score Matching 17 4.2.6.3 Statistical Software 18 4.3 Aim 3: Cost-Effectiveness Analysis of the PAWM 19 4.3.1 Markov Model 19 4.3.2 Likelihood of Events 20 4.3.2.1 INR Transition Probabilities 21 4.3.2.2 Probabilities of Developing Major TE and Major Bleeding Events 23 4.3.2.3 Proportions of Major TE and Major Bleeding Event Subtypes 23 4.3.2.4 Probabilities of Developing Sequelae 24 4.3.2.5 Probabilities of Death 24 4.3.3 Costs 25 4.3.3.1 Costs of the INR Testing 26 4.3.3.2 Costs of the PAWM Service and Set-up 26 4.3.3.3 Costs of Major TE and Major Bleeding Events and Sequelae 27 4.3.4 Utilities 28 4.3.5 Discounting 28 4.3.6 Base-Case Analysis 28 4.3.7 Sensitivity Analyses 29 4.3.8 Statistical Software 30 Chapter 5: Results 31 5.1 Patient Characteristics of the Study Cohort 31 5.2 Clinical Outcomes of the PAWM 33 5.2.1 Time in Therapeutic Range 33 5.2.2 Major TE and Major Bleeding Events 33 5.3 Cost-Effectiveness of the PAWM 35 5.3.1 Base-Case Analysis 35 5.3.2 One-way Sensitivity Analysis and Probabilistic Sensitivity Analysis 35 5.3.3 Scenario Sensitivity analyses 36 Chapter 6: Discussions 38 6.1 Clinical Outcomes of the PAWM 38 6.2 Cost-Effectiveness of the PAWM 43 6.3 Strengths 49 6.4 Limitations 51 Chapter 7: Conclusions and Recommendations 54 Figures 55 Tables 64 References 77 | |
dc.language.iso | en | |
dc.title | 某醫學中心抗凝血藥師門診監測warfarin療效的成本效益分析 | zh_TW |
dc.title | Cost-Effectiveness of the Pharmacist-assisted Warfarin Monitoring Program (PAWM) at a Medical Center | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 王繼娟(Chi-Chuan Wang) | |
dc.contributor.oralexamcommittee | 張睿詒(Ray-E Chang) | |
dc.subject.keyword | warfarin,抗凝血門診藥師監測warfarin,INR控制,療效評估,成本效益分析,增加成本效益比,品質校正生活年, | zh_TW |
dc.subject.keyword | warfarin,pharmacist-assisted warfarin monitoring (PAWM),INR control,clinical effectiveness,cost-effectiveness,incremental cost-effectiveness ratio (ICER),quality-adjusted life-year (QALY), | en |
dc.relation.page | 89 | |
dc.identifier.doi | 10.6342/NTU201602138 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-09 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。